Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Oct-24 11:25 AM View:  | Leonard Braden Michael | Onkure Therapeutics, Inc. (OKUR) | 07-Oct-24 | Acquisition (other) | 345,739 | -- | -- | 100% 0 to 345.74K | |
| 09-Oct-24 11:25 AM View: | Leonard Braden Michael | Onkure Therapeutics, Inc. (OKUR) | 07-Oct-24 | Acquisition (other) | 102,076 | -- | -- | 30% 345.74K to 447.81K | |
| 08-Oct-24 7:29 PM View: | Saccomano Nicholas A President and CEO Director | Onkure Therapeutics, Inc. (OKUR) | 04-Oct-24 | Grant | 4,556 | -- | -- | 100% 0 to 4.56K | |
| 08-Oct-24 7:21 PM View: | Carruthers R Michael Director | Onkure Therapeutics, Inc. (OKUR) | 04-Oct-24 | Grant | 4,939 | -- | -- | 100% 0 to 4.94K | |
| 08-Oct-24 7:26 PM View: | Leverone Jason A. Chief Financial Officer | Onkure Therapeutics, Inc. (OKUR) | 04-Oct-24 | Grant | 16,331 | -- | -- | 100% 0 to 16.33K | |
| 26-Sep-24 9:33 AM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 25-Sep-24 | Purchase | 68,746 | $1.50 | $102,872.00 | 2% 4.41M to 4.48M | |
| 26-Sep-24 9:33 AM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 24-Sep-24 | Private Purchase | 29,600 | $1.41 | $41,866.20 | < 1% 4.38M to 4.41M | |
| 19-Sep-24 11:02 AM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 18-Sep-24 | Purchase | 806 | $1.40 | $1,128.40 | < 1% 4.38M to 4.38M | |
| 19-Sep-24 11:02 AM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 17-Sep-24 | Private Purchase | 55,300 | $1.36 | $75,108.50 | 1% 4.32M to 4.38M | |
| 16-Sep-24 4:15 PM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 16-Sep-24 | Purchase | 172,747 | $1.37 | $236,871.00 | 4% 4.15M to 4.32M | |
| 16-Sep-24 4:15 PM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 13-Sep-24 | Purchase | 150,000 | $1.31 | $196,950.00 | 4% 4.0M to 4.15M | |
| 16-Sep-24 4:15 PM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 12-Sep-24 | Private Purchase | 36,176 | $1.40 | $50,523.40 | < 1% 3.96M to 4.0M | |
| 14-Aug-24 8:48 PM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 14-Aug-24 | Purchase | 100,487 | $1.41 | $142,008.00 | 3% 3.86M to 3.96M | |
| 14-Aug-24 8:48 PM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 13-Aug-24 | Private Purchase | 171,339 | $1.39 | $238,590.00 | 5% 3.69M to 3.86M | |
| 16-May-24 8:58 AM View: | Leonard Braden Michael 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 14-May-24 | Private Purchase | 414,281 | $1.54 | $639,578.00 | 13% 3.28M to 3.69M | |
| 29-Aug-23 5:04 PM View: | Hall Ashley Chief Development Officer | Onkure Therapeutics, Inc. (OKUR) | 28-Aug-23 | Option Exercise | 15,625 | $1.80 | $28,125.00 | 39% 39.6K to 55.23K | |
| 29-Aug-23 5:04 PM View: | Hall Ashley Chief Development Officer | Onkure Therapeutics, Inc. (OKUR) | 28-Aug-23 | Option Sale | 15,625 | $6.28 | $98,057.80 | (28%) 55.23K to 39.6K | |
| 27-Jul-23 5:16 PM View: | Grey Michael G Executive Chairman Director | Onkure Therapeutics, Inc. (OKUR) | 26-Jul-23 | Gift | 50,000 | -- | -- | (7%) 678.85K to 628.85K | |
| 23-Jun-23 7:15 PM View: | Novo A/s 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 23-Jun-23 | Sale | 100,000 | $7.10 | $709,740.00 | (3%) 3.43M to 3.33M | |
| 10-May-23 5:47 PM View: | O'Donnell Niall Director | Onkure Therapeutics, Inc. (OKUR) | 08-May-23 | Private Purchase | 125,000 | $8.00 | $1,000,000.00 | 6% 2.06M to 2.19M | |
| 02-Sep-22 5:12 PM View: | Cruse Michael Chief Operating Officer | Onkure Therapeutics, Inc. (OKUR) | 01-Sep-22 | Private Purchase | 7,500 | $3.39 | $25,447.50 | 20% 37.95K to 45.45K | |
| 02-Sep-22 5:10 PM View: | Grey Michael G Executive Chairman Director | Onkure Therapeutics, Inc. (OKUR) | 31-Aug-22 | Option Exercise | 50,000 | $1.97 | $98,500.00 | 9% 578.85K to 628.85K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Onkure Therapeutics, Inc. (OKUR) | 31-Aug-22 | Purchase | 3,212 | $3.21 | $10,307.30 | 9% 34.74K to 37.95K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Onkure Therapeutics, Inc. (OKUR) | 30-Aug-22 | Purchase | 975 | $3.16 | $3,081.00 | 3% 31.92K to 32.9K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Onkure Therapeutics, Inc. (OKUR) | 30-Aug-22 | Purchase | 1,845 | $3.19 | $5,892.56 | 6% 32.9K to 34.74K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Onkure Therapeutics, Inc. (OKUR) | 29-Aug-22 | Purchase | 1,140 | $3.24 | $3,693.60 | 4% 30.78K to 31.92K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Onkure Therapeutics, Inc. (OKUR) | 29-Aug-22 | Private Purchase | 83 | $3.24 | $268.92 | < 1% 30.7K to 30.78K | |
| 13-Dec-22 6:07 PM View: | Dorenbaum Alejandro Chief Medical Officer | Onkure Therapeutics, Inc. (OKUR) | 12-Aug-22 | Gift | 22,348 | -- | -- | (43%) 52.35K to 30.0K | |
| 14-Dec-21 4:28 PM View: | Cruse Michael Senior VP-Corporate Operations | Onkure Therapeutics, Inc. (OKUR) | 10-Dec-21 | Grant | 25,000 | -- | -- | 610% 4.1K to 29.1K | |
| 14-Dec-21 4:31 PM View: | Flesher Gregory J. President and CEO Director | Onkure Therapeutics, Inc. (OKUR) | 10-Dec-21 | Grant | 100,000 | -- | -- | 1042% 9.6K to 109.6K | |
| 14-Dec-21 4:30 PM View: | Dorenbaum Alejandro Chief Medical Officer | Onkure Therapeutics, Inc. (OKUR) | 10-Dec-21 | Grant | 30,000 | -- | -- | 134% 22.35K to 52.35K | |
| 14-Dec-21 4:32 PM View: | Jindal Vineet R. Chief Financial Officer | Onkure Therapeutics, Inc. (OKUR) | 10-Dec-21 | Grant | 30,000 | -- | -- | 455% 6.6K to 36.6K | |
| 15-Nov-21 7:49 PM View: | Hall Ashley Chief Development Officer | Onkure Therapeutics, Inc. (OKUR) | 12-Nov-21 | Grant | 30,000 | -- | -- | 100% 0 to 30.0K | |
| 26-Aug-21 5:54 PM View: | Jindal Vineet R. Chief Financial Officer | Onkure Therapeutics, Inc. (OKUR) | 25-Aug-21 | Market Purchase | 5,000 | $7.44 | $37,176.50 | 100% 0 to 5.0K | (5%) |
| 26-Aug-21 5:51 PM View: | Cruse Michael Senior VP-Corporate Operations | Onkure Therapeutics, Inc. (OKUR) | 25-Aug-21 | Market Purchase | 2,500 | $7.45 | $18,616.00 | 100% 0 to 2.5K | (5%) |
| 26-Aug-21 5:52 PM View: | Flesher Gregory J. President and CEO Director | Onkure Therapeutics, Inc. (OKUR) | 25-Aug-21 | Market Purchase | 8,000 | $8.00 | $64,000.00 | 100% 0 to 8.0K | (12%) |
| 15-Jul-21 5:34 PM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 14-Jul-21 | Market Purchase | 111,736 | $8.50 | $949,756.00 | 6% 1.96M to 2.07M | 2% |
| 15-Jul-21 5:33 PM View: | Johnson Wendy S. Chief Development Officer | Onkure Therapeutics, Inc. (OKUR) | 14-Jul-21 | Market Sale | 111,736 | $8.50 | $949,756.00 | (100%) 111.74K to 0 | (2%) |
| 09-Jul-21 6:52 PM View: | Johnson Wendy S. Chief Development Officer | Onkure Therapeutics, Inc. (OKUR) | 08-Jul-21 | Option Exercise | 111,736 | $1.97 | $220,120.00 | 100% 0 to 111.74K | |
| 25-Jun-21 9:00 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 23-Jun-21 | Market Purchase | 20,710 | $9.28 | $192,245.00 | 1% 1.94M to 1.96M | 4% |
| 23-Jun-21 8:33 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 22-Jun-21 | Market Purchase | 14,615 | $8.72 | $127,487.00 | < 1% 1.93M to 1.94M | 5% |
| 23-Jun-21 8:33 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 21-Jun-21 | Market Purchase | 32,659 | $9.03 | $294,927.00 | 2% 1.89M to 1.93M | 1% |
| 10-Jun-21 9:00 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 08-Jun-21 | Market Purchase | 16,605 | $9.50 | $157,709.00 | < 1% 1.88M to 1.89M | 2% |
| 07-Jun-21 8:53 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 04-Jun-21 | Market Purchase | 257 | $9.42 | $2,422.02 | < 1% 1.88M to 1.88M | 3% |
| 07-Jun-21 8:53 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 03-Jun-21 | Market Purchase | 12,100 | $9.25 | $111,943.00 | < 1% 1.87M to 1.88M | 5% |
| 02-Jun-21 10:37 AM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 28-May-21 | Private Purchase | 14 | $9.50 | $133.00 | < 1% 1.87M to 1.87M | |
| 28-May-21 4:10 PM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 27-May-21 | Market Purchase | 1,120 | $9.26 | $10,369.30 | < 1% 1.86M to 1.87M | 4% |
| 28-May-21 4:10 PM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 26-May-21 | Market Purchase | 5,915 | $9.38 | $55,495.10 | < 1% 1.86M to 1.86M | 3% |
| 14-Apr-21 4:44 PM View: | Novo A/s 10% Owner | Onkure Therapeutics, Inc. (OKUR) | 13-Apr-21 | Conversion | 2,763,710 | -- | -- | 100% 0 to 2.76M | |
| 15-Apr-21 4:15 PM View: | Muralidhar Bali Director | Onkure Therapeutics, Inc. (OKUR) | 13-Apr-21 | Conversion | 1,658,230 | -- | -- | 100% 0 to 1.66M |
